Blockchain Registration Transaction Record

Helus Pharma Presents HLP003 Data at Psych Congress 2026

Helus Pharma presents four posters on HLP003, an oral psilocin analog for major depressive disorder, at Psych Congress 2026, including Phase 3 PARADIGM overview.

The presentation of promising 12-month efficacy and safety data for HLP003 at Psych Congress 2026 underscores the potential of novel serotonergic agonists as a new class of antidepressants. With major depressive disorder affecting millions worldwide and many patients not achieving adequate relief from existing therapies, HLP003's Breakthrough Therapy Designation and advancement into Phase 3 trials signal a possible paradigm shift. If approved, HLP003 could offer a much-needed adjunctive treatment option that provides durable improvements, addressing a significant unmet need in mental health care. This news matters because it brings hope for more effective, fast-acting, and long-lasting depression treatments, potentially transforming the lives of those who struggle with this debilitating condition.